Expert Interview
A look at the updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
Ticker(s): BOEHRINGER INGELHEIMInstitution: UCSF
- Medical oncologist and molecular biologist specializing in lung cancer, with a focus on the biology of tumor initiation, progression, and drug resistance
- Treats approximately 200–250 new patients with non-small cell lung cancer (NSCLC) per year
- Primary research focuses on signal transduction, cancer genetics, and resistance mechanisms, including RAS signaling via cytoplasmic protein granules, NF-kappaB and Hippo-YAP pathways, and lineage plasticity
How do you interpret the efficacy signals seen with zongertinib in the context of existing treatment options for HER2-mutant NSCLC, particularly in previously treated patients?
Added By: sara_adminWhat are your thoughts on the safety and tolerability profile of zongertinib from the Beamion LUNG-1 data, and how might this influence its integration into clinical practice?
Given the heterogeneity of HER2 alterations in NSCLC, including exon 20 insertions and amplifications, how selective is zongertinib's activity across these subtypes based on what we've seen so far?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
